Programa Nacional de Control de la Tuberculosis: Normas Técnicas 2013

Fil: Zerbini, Elsa V. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Argentina.Fil: Cudos, C. Ministerio de Salud de la Provincia de Santa Fe, Santa Fe, Argentina

Programa Nacional de Control de la Tuberculosis: Normas Técnicas 2013

Fil: Zerbini, Elsa V. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Argentina.Fil: Cudos, C. Ministerio de Salud de la Provincia de Santa Fe, Santa Fe, Argentina

Antibody response to culture filtrate antigens of Mycobacterium tuberculosis during and after treatment of tuberculosis patients

Fil: Imaz, María Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Santa Fe, Argentina.Fil: Zerbini, Elsa V. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Santa Fe, Argentina.SETTING: Many authors have shown rising titres of antimycobacterial antibodies after a few months of antituberculosis treatment. This humoral response might persist for years, making the discrimination between current and old disease difficult. OBJECTIVE: Characterisation of the humoral response to culture filtrates of Mycobacterium tuberculosis before and after treatment of tuberculous patients in order to identify those antigens that could provide information about disease activity. METHODS: Anti-mycobacterial IgG response was determined during and after treatment of tuberculous patients by ELISA and immunoblot. Serum was taken from 71 active tuberculous patients (59 newly acquired and 12 relapse), 15 old tuberculous patients and 45 nontuberculous control subjects. RESULTS: By ELISA, antibody response increased after 2 months of treatment. After chemotherapy was completed, the estimated number of antibodies remained at the same level. The level of specific antibodies in patients seems to reach the same level as that of control subjects 3 years after initiation of treatment. In Western blot, although each patient serum had its own characteristic banding pattern, differences between tuberculous patients and control subjects were found in the area below 20 kDa. Serum from tuberculous patients showed high levels of antibodies at the 14 kDa region. After the beginning of treatment, the intensity of the 14 kDa region band and the percentage of positive recognition tended to decrease. Therefore, one year after initiation of treatment, only seven of 13 cases who demonstrated antimycobacterial antibodies in ELISA revealed a mild but still positive reaction at the 14 kDa region; this reactivity disappeared 2 years after initiation of chemotherapy. CONCLUSIONS: The 14 kDa region antigen seems to induce a humoral response that evolves in relation with the disease activit

Antibody response to culture filtrate antigens of Mycobacterium tuberculosis during and after treatment of tuberculosis patients

Fil: Imaz, María Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Santa Fe, Argentina.Fil: Zerbini, Elsa V. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Santa Fe, Argentina.SETTING: Many authors have shown rising titres of antimycobacterial antibodies after a few months of antituberculosis treatment. This humoral response might persist for years, making the discrimination between current and old disease difficult. OBJECTIVE: Characterisation of the humoral response to culture filtrates of Mycobacterium tuberculosis before and after treatment of tuberculous patients in order to identify those antigens that could provide information about disease activity. METHODS: Anti-mycobacterial IgG response was determined during and after treatment of tuberculous patients by ELISA and immunoblot. Serum was taken from 71 active tuberculous patients (59 newly acquired and 12 relapse), 15 old tuberculous patients and 45 nontuberculous control subjects. RESULTS: By ELISA, antibody response increased after 2 months of treatment. After chemotherapy was completed, the estimated number of antibodies remained at the same level. The level of specific antibodies in patients seems to reach the same level as that of control subjects 3 years after initiation of treatment. In Western blot, although each patient serum had its own characteristic banding pattern, differences between tuberculous patients and control subjects were found in the area below 20 kDa. Serum from tuberculous patients showed high levels of antibodies at the 14 kDa region. After the beginning of treatment, the intensity of the 14 kDa region band and the percentage of positive recognition tended to decrease. Therefore, one year after initiation of treatment, only seven of 13 cases who demonstrated antimycobacterial antibodies in ELISA revealed a mild but still positive reaction at the 14 kDa region; this reactivity disappeared 2 years after initiation of chemotherapy. CONCLUSIONS: The 14 kDa region antigen seems to induce a humoral response that evolves in relation with the disease activit

In-vitro activity of two hybrid synthetic peptides having antimicrobial activity against mycobacteria

Fil: Zerbini, E. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Argentina.Fil: Andreu, D. Universidad de Pompeu Favra. Laboratorio de Síntesis; España.Fil: Tonarelli, G. Universidad Nacional del Litoral. Departamento de Química Orgánica; Argentina.Fil: Sequeira, M. D. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Argentina.El aumento de aislamientos clínicos de Mycobacterium tuberculosis resistentes a las drogas esenciales y de casos de micobacteriosis diseminadas debidas al complejo Mycobacterium avium hacen necesario investigar nuevos agentes antimicobacterianos. Los péptidos antimicrobianos son un nuevo grupo de antibióticos que poseen un mecanismo de acción particular. Algunos de ellos, como la cecropina y la melitina, han sido aislados de insectos y han demostrado buena actividad in vitro contra bacterias gram positivas y gram negativas. Híbridos sintéticos de esos péptidos han presentado mayor actividad que los péptidos individuales. En este trabajo se evaluó la actividad in vitro de dos péptidos híbridos sintéticos de melitina y cecropina contra M. tuberculosis, complejo M. avium, Mycobacterium fortuitum y Mycobacterium smegmatis. Se determinó la concentración inhibitoria mínima empleando la técnica de macrodilución en caldo. Luego se estableció la concentración bactericida mínima en medio Lowenstein Jensen. Los péptidos evaluados mostraron ser activos in vitro contra M. smegmatis, mientras que no presentaron ninguna actividad contra las otras micobacterias estudiadas

In-vitro activity of two hybrid synthetic peptides having antimicrobial activity against mycobacteria

Fil: Zerbini, E. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Argentina.Fil: Andreu, D. Universidad de Pompeu Favra. Laboratorio de Síntesis; España.Fil: Tonarelli, G. Universidad Nacional del Litoral. Departamento de Química Orgánica; Argentina.Fil: Sequeira, M. D. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Argentina.El aumento de aislamientos clínicos de Mycobacterium tuberculosis resistentes a las drogas esenciales y de casos de micobacteriosis diseminadas debidas al complejo Mycobacterium avium hacen necesario investigar nuevos agentes antimicobacterianos. Los péptidos antimicrobianos son un nuevo grupo de antibióticos que poseen un mecanismo de acción particular. Algunos de ellos, como la cecropina y la melitina, han sido aislados de insectos y han demostrado buena actividad in vitro contra bacterias gram positivas y gram negativas. Híbridos sintéticos de esos péptidos han presentado mayor actividad que los péptidos individuales. En este trabajo se evaluó la actividad in vitro de dos péptidos híbridos sintéticos de melitina y cecropina contra M. tuberculosis, complejo M. avium, Mycobacterium fortuitum y Mycobacterium smegmatis. Se determinó la concentración inhibitoria mínima empleando la técnica de macrodilución en caldo. Luego se estableció la concentración bactericida mínima en medio Lowenstein Jensen. Los péptidos evaluados mostraron ser activos in vitro contra M. smegmatis, mientras que no presentaron ninguna actividad contra las otras micobacterias estudiadas

[Trends of tuberculosis in the Fifth Health Region, Buenos Aires Province, years 2000-2011]

The aim of this study was to describe the trends in tuberculosis (TB) in the Fifth Health Region (RSV) in the Buenos Aires Province. A trend study allowed the evaluation of the average variation of change in the incidence rate (IR) using simple linear regression expressed as a mean annual variation (VAP). The number of reported TB cases and IR per 100 000 population of all TB cases, pulmonary TB (PTB) and bacteriologically confirmed PTB from January 1, 2000 to December 31, 2011, were analyzed by age groups: 0-14; 15-29 and over 64 years of age. The decline in IR was less than 5% for all forms of TB and lower for bacteriologically confirmed PTB cases. The highest rate of PTB and IR was concentrated in the age group of 15-29 years with stable or slightly increasing trend of IR in bacteriologically confirmed PTB. There were similar trends for bacteriologically confirmed PTB in children. The fastest decline in PTB IR occurred in 0-14 age group, while for cases over 64 years of age the decline was sustained over time. TB continues to be a health risk in RSV, with cases in younger age groups. Therefore, it remains necessary to strengthen TB control activities in this region

[Trends of tuberculosis in the Fifth Health Region, Buenos Aires Province, years 2000-2011]

The aim of this study was to describe the trends in tuberculosis (TB) in the Fifth Health Region (RSV) in the Buenos Aires Province. A trend study allowed the evaluation of the average variation of change in the incidence rate (IR) using simple linear regression expressed as a mean annual variation (VAP). The number of reported TB cases and IR per 100 000 population of all TB cases, pulmonary TB (PTB) and bacteriologically confirmed PTB from January 1, 2000 to December 31, 2011, were analyzed by age groups: 0-14; 15-29 and over 64 years of age. The decline in IR was less than 5% for all forms of TB and lower for bacteriologically confirmed PTB cases. The highest rate of PTB and IR was concentrated in the age group of 15-29 years with stable or slightly increasing trend of IR in bacteriologically confirmed PTB. There were similar trends for bacteriologically confirmed PTB in children. The fastest decline in PTB IR occurred in 0-14 age group, while for cases over 64 years of age the decline was sustained over time. TB continues to be a health risk in RSV, with cases in younger age groups. Therefore, it remains necessary to strengthen TB control activities in this region

Delay in tuberculosis diagnosis and treatment in four provinces of Argentina

Public health care services in the provinces of Buenos Aires, Santa Fe, Jujuy and Santa Cruz, Argentina